| TKO |
Report |
Adjusted EBITDA (Q2 2026) |
BEAT |
pred ~$655M vs. cons $636.2M |
MEDIUM |
| TKO |
Report |
WWE Revenue (Q2 2026) |
BEAT |
pred ~$635M vs. cons $619.7M |
MEDIUM |
| TKO |
Report |
Partnerships & Marketing Revenue (Q2 2026) |
BEAT |
pred ~$205M vs. cons $198.7M |
MEDIUM |
| TKO |
Guide |
FY 2026 Adj. EBITDA (FY 2026) |
UNCHANGED |
guide reaffirm $2,240M-$2,290M vs. cons $2,273M |
MEDIUM |
| TKO |
Guide |
FY 2026 Revenue (FY 2026) |
UNCHANGED |
guide reaffirm $5,675B-$5,775B vs. cons $5,766M |
MEDIUM |
| TKO |
Guide |
Capital Returns / Buyback (qualitative) |
BETTER |
guide continuation of $200M 10b5-1 + color on remaining $1B+ authorization vs. no consensus |
MEDIUM |
| TKO |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.0% |
— |
MEDIUM |
| TKO |
Return |
5-day cumulative residual |
-1.5% (STABILIZE) |
STABILIZE — short covering limits further downside; no FY raise to drive estimate upgrades; EBITDA revision trend stops bleeding but does not reverse |
MEDIUM |